The cancer diagnostics and treatment company priced above its previously planned range and might signal a renewed appetite for biotech IPOs.

The stock of Caris Life Sciences shined in its Nasdaq debut on Wednesday, pricing its heavily-subscribed initial public offering at $21 per share and

Caris Life Sciences Inc., a health-care company that uses technology to help diagnose and treat cancer, raised $494 million in a US initial public offering that priced above the top of its marketed range.